Finland· FI-REL-REL27367
Tyverb
A lapatinib product containing lapatinib ditosylate monohydrate, registered in Finland by Novartis Europharm Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Lapatinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EH01 (lapatinib), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Lapatinib · ATC L01EH01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of lapatinib costs, country by country.
Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lapatinib · price per daily dose (1.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$101.12
The record
At a glance
Fimea (Finland)- Active substance
- Lapatinib ditosylate monohydrate
- Manufacturer
- Novartis Europharm Limited
- Country
- Finland (FI)
- ATC code
- L01EH01
- ATC class
- Lapatinib
- Defined daily dose
- 1.25 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa38421170EUR 1260.66
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
675 interactions on record for lapatinib.
Graded by severity as the source publishes them — 124 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lapatinib · interactions on record
675 records
- 124 severe
- 537 moderate
- 14 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LoperamideA07DA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lapatinib in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/acde7549-64c2-4555-99ba-0f464d867207 GET /v1/drugs/acde7549-64c2-4555-99ba-0f464d867207?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "1.25",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "g",
"strength": "250 mg",
"atc_label": "lapatinibi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/07/440/001-007",
"fimea_rel_id": "REL27367",
"authorised_at": "2008-06-10"
}See everything about lapatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.